2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Na+/K+ ATPase
  5. Na+/K+ ATPase Inhibitor

Na+/K+ ATPase Inhibitor

Na+/K+ ATPase Inhibitors (43):

Cat. No. Product Name Effect Purity
  • HY-B0542
    Ouabain Octahydrate
    		Inhibitor 99.96%
    Ouabain Octahydrate is an inhibitor of Na+/K+-ATPase, used for the treatment of congestive heart failure.
  • HY-N0039
    Ginsenoside Rb1
    		Inhibitor 98.75%
    Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with an IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65 .
  • HY-N0877
    Bufalin
    		Inhibitor 99.86%
    Bufalin is an active component isolated from Chan Su, acts as a potent Na+/K+-ATPase inhibitor, binds to the subunit α1, α2 and α3, with Kd of 42.5, 45 and 40 nM, respectively. Anti-cancer activity.
  • HY-124404
    12(R)-HETE
    		Inhibitor
    12(R)-HETE is a metabolite of Arachidonic acid, AA (HY-109590) and can be found in skin from psoriatic lesions. 12(R)-HETE induces lymphocytes chemotaxis, stimulates calcium mobilization and chemotaxis in neutrophils via the BLT1 receptor, activates the aryl hydrocarbon receptor, and inhibits Na+/K+ ATPase activity in the corneal epithelium.
  • HY-116196
    17-HETE
    		Inhibitor
    17-HETE is arachidonic acid metabolite through cytochrome P-450 pathways, which consists of 17R-HETE and 17S-HETE enantiomers. 17-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy.
  • HY-A0154R
    Deslanoside (Standard)
    		Inhibitor
    Deslanoside (Standard) is the analytical standard of Deslanoside. This product is intended for research and analytical applications. Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
  • HY-B0401
    Tolbutamide
    		Inhibitor 99.96%
    Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete.
  • HY-15718A
    Istaroxime hydrochloride
    		Inhibitor 99.32%
    Istaroxime hydrochloride is a Na+/K+-ATPase inhibitor (IC50=0.11 μM) and a sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA 2) activator.
  • HY-N0143
    Phlorizin
    		Inhibitor 99.82%
    Phlorizin (Floridzin) is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na+/K+-ATPase inhibitor.
  • HY-13719
    Oleandrin
    		Inhibitor 99.93%
    Oleandrin (PBI-05204) inhibits the Na+, K+-ATPase activity with an IC50 of 620 nM.
  • HY-A0154
    Deslanoside
    		Inhibitor 99.79%
    Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
  • HY-114252
    Strophanthidin
    		Inhibitor
    Strophanthidin is a naturally available cardiac glycoside. Strophanthidin 0.1 and 1 nmol/L increases and 1~100 µmol/L inhibits the Na+/K+-ATPase activities, but Strophanthidin 10 and 100 nmol/L does not affect Na+/K+-ATPase activities in cardiac sarcolemmal. Strophanthidin increases both diastolic and systolic intracellular Ca2+ concentration.
  • HY-Y0413
    Biacetyl monoxime
    		Inhibitor ≥98.0%
    Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca2+ release.
  • HY-B0137
    Prilocaine
    		Inhibitor 99.87%
    Prilocaine, an amino amide, is a Na, K-ATPase inhibitor. Prilocaine has neurotoxic effects.
  • HY-N8441
    Neriifolin
    		Inhibitor 99.43%
    Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na+, K+-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells[2.
  • HY-19556
    (+)-SJ733
    		Inhibitor 99.45%
    (+)-SJ733 is an anti-malaria agent which can also inhibit Na+-ATPase PfATP4.
  • HY-B1429
    Chlorpropamide
    		Inhibitor 99.39%
    Chlorpropamide is an oral hypoglycemic agent studied in non-insulin-dependent diabetes mellitus (NIDDM).
  • HY-P1565A
    Transdermal Peptide Disulfide TFA
    		Inhibitor 99.38%
    Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a 11-amino acid peptide, binds to Na+/K+-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide TFA can enhance the transdermal delivery of many macromolecules.
  • HY-N2070
    Acevaltrate
    		Inhibitor 99.56%
    Acevaltrate inhibits the Na+/K+-ATPase activity in the rat kidney and brain hemispheres with IC50s of 22.8 μM and 42.3 μM, respectively.
  • HY-B1604
    Chloroprocaine hydrochloride
    		Inhibitor 99.89%
    Chloroprocaine hydrochloride (2-Chloroprocaine hydrochloride) is a potent inhibitor of Na,K-ATPase activity with an IC50 of 13 mM. Chloroprocaine hydrochloride blocks peripheral nerve.